Greenwich LifeSciences GLSI 深 沪
已收盘 09-19 16:00:00 美东时间
11.46
-0.080
-0.69%
华盛通- 最 高11.66
- 今 开11.59
- 成交量 10.47万股
- 最 低 11.20
- 昨 收 11.54
- 总市值 1.53亿
- 52周最高 15.47
- 市盈率 静 --
- 换手率 0.78%
- 52周最低 8.06
- 委 比 -22.04%
- 总股本 1336.83万
- 历史最高 158.07
- 量 比 1.31
- 振 幅 3.99%
- 历史最低 3.262
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Greenwich LifeSciences expands breast cancer trial to Ireland
Greenwich LifeSciences (NASDAQ:GLSI) said it has expanded its Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, to Ireland. The company's applicat...
09-18 18:25
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 239.0% to ...
09-10 20:11
The FDA Has Granted Fast Track Designation To Greenwich Lifesciences' GLSI-100 In HLA-A*02 Patient Population
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
09-10 18:03
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
Greenwich LifeSciences' GLSI-100 immunotherapy has received FDA Fast Track designation for HLA-A*02 breast cancer patients, aiming to prevent metastatic recurrence. This designation may accelerate drug approval via more frequent FDA communication and rolling BLA review. Previously, Phase IIb data showed an 80% reduction in recurrence rates, with no serious adverse events. The Phase III FLAMINGO-01 trial is ongoing, targeting 500 HLA-A*02 patients...
09-10 10:00
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
Greenwich LifeSciences announced that Noble Capital Markets has initiated equity research coverage on the company. The company is focused on its Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy for preventing breast cancer recurrences in HER2 positive patients. The trial aims to enroll up to 750 patients globally and is led by Baylor College of Medicine. For more details, visit the company's website or clinicaltrials.gov.
08-20 13:25
Greenwich LifeSciences Cuts Costs by Bringing Breast Cancer Trial Management In-House
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
08-19 18:04
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
Greenwich LifeSciences announced plans to build its internal clinical trial management team to reduce reliance on external CROs, lowering costs and improving efficiency for its Phase III FLAMINGO-01 trial evaluating GLSI-100 for breast cancer prevention. The company is hiring dedicated staff to manage the trial, which includes up to 150 global sites and approximately 750 patients, aiming to enhance data quality and flexibility for future trials.
08-19 10:00
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
Greenwich LifeSciences expands its FLAMINGO-01 clinical trial into Romania, adding sites to its existing 150 global locations. The trial evaluates GLSI-100, an immunotherapy for preventing breast cancer recurrence. Romania, with 12,861 new breast cancer cases in 2022, is the first European country added. Collaborating with Dr. Nicoleta Antone, a leading breast cancer expert, the company aims to enroll Romanian patients soon. FLAMINGO-01 is a Phas...
08-13 10:00
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
Greenwich LifeSciences, a clinical-stage biopharmaceutical company, focuses on developing GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company recently provided updates on CEO interviews and corporate events, including videos of interviews available on their website. Greenwich LifeSciences is currently conducting the FLAMINGO-01 Phase III clinical trial for GLSI-100 in HER2-positive breast cancer patients. The trial aims t...
08-11 10:00
Greenwich LifeSciences Q1 EPS $(0.25) Down From $(0.19) YoY
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.25) per share. This is a 31.58 percent decrease over losses of $(0.19) per share from the same period last year.
05-21 05:58
